Dyadic International (NASDAQ:DYAI – Get Free Report) and Kezar Life Sciences (NASDAQ:KZR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Risk and Volatility
Dyadic International has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Kezar Life Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
Earnings and Valuation
This table compares Dyadic International and Kezar Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dyadic International | $1.81 million | 18.43 | -$5.81 million | ($0.24) | -3.85 |
| Kezar Life Sciences | $7.00 million | 6.49 | -$83.74 million | ($8.44) | -0.74 |
Dyadic International has higher earnings, but lower revenue than Kezar Life Sciences. Dyadic International is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Dyadic International and Kezar Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dyadic International | -134.84% | -355.39% | -60.66% |
| Kezar Life Sciences | N/A | -62.53% | -51.77% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Dyadic International and Kezar Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dyadic International | 1 | 0 | 2 | 0 | 2.33 |
| Kezar Life Sciences | 2 | 4 | 0 | 0 | 1.67 |
Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 224.68%. Kezar Life Sciences has a consensus price target of $6.00, indicating a potential downside of 3.32%. Given Dyadic International’s stronger consensus rating and higher probable upside, equities analysts clearly believe Dyadic International is more favorable than Kezar Life Sciences.
Insider & Institutional Ownership
28.0% of Dyadic International shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 29.5% of Dyadic International shares are held by company insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Dyadic International beats Kezar Life Sciences on 8 of the 14 factors compared between the two stocks.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
